Benefit–risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment

摘要

ObjectivesTo conduct the benefit–risk assessment of 3-hydroxy-3-methyl-glutaryl (HMG) coenzyme A reductase inhibitors (statins) using a discrete choice experiment, based on 3 major stakeholders’ perspectives including patients, experts and policymakers in Thailand.